Аспекты эффективности антибиотиков

1. Rothrock SG, Green SM, Harper MB et al. Parenteral vs Oral Antibiotics in the Prevention of Serious Bacterial Infections in Children with Streptococcus pneumoniae Occult Bacteremia: A Meta-Analysis. Acad Emerg Med 1998; (6): 599–606.
2. Rimoin AW, Hoff NA, Fischer Walker CL et al. Treatment of streptococcal pharyngitis with once-daily amoxicillin versus intramuscular benzathine penicillin G in low-resource settings: a randomized controlled trial. (Phila) Clin Pediatr 2011; 50 (6): 535–42.
3.Wang CY, Lu CY, Hsieh YC et al. Intramuscular ceftriaxone in comparison with oral amoxicillin-clavulanate for the treatment of acute otitis media in infants and children. J Microbiol Immunol Infect 2004; 37 (1): 57–62.
4. Lodha R, Kabra SK, Pandey RM. Antibiotics for community-acquired pneumonia in children (review). The Cochrane Library 2013; 6: 1–195; http://www.thecochranelibrary.com
5. Halperin JJ, Shapiro ED, Logigian E et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the Am Acad Neurology. Neurology 2007; 69 (1): 91–102.
6. Plourde PJ, Tyndall M, Agoki E et al. Single-dose cefixime versus single-dose ceftriaxone in the treatment of antimicrobial-resistant Neisseria gonorrhoeae infection. J Infect Dis 1992; 166 (4): 919–22.
7. Portilla I, Lutz B, Montalvo M, Mogabgab WJ. Oral cefixime versus intramuscular ceftriaxone in patients with uncomplicated gonococcal infections. Sex Transm Dis 1992; 19 (2): 94–8.
8. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике. Российские практические рекомендации. Под. ред. С.В.Яковлева, С.В.Сидоренко, В.В.Рафальского, Т.В.Спичак. М.: ПРЕ100 ПРИНТ, 2014.
9. Карпов О.И., Рязанцев С.В., Тихомирова И.А. Путь повышения эффективности и переносимости антибиотикотерапии при синусите у детей. Детские инфекции. 2006; 3: 57–60.
10. http://www.grls.rosminzdrav.ru. 07.07.2014
11. Cortvriendt WR et al. Bioavilability study of new amoxicillin tablet designed for several modes of oral administration. Arzneimittelforschung 1987; 37 (8): 977–9.
12. Моисеев С.В. Роль амоксициллина в лечении распространенных внебольничных инфекций. Клин. фармакология и терапия. 2006; 15 (1):  1–4.
13. Sourgens H et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator film-coated tablet. Int J Clin Pharm Ther 2001; 39 (2): 75–82.
14. Bergan T, Tolas P, Oydvin B. Influence of food and hepatobiliary disease on the excretion of josamycin. Phaflllacology 1972; 8: 336–43.
15. Van Hoogdalem EJ, Terpstra IJ, Krauwinkel WJ et al. Multiple dose bioequivalence study with josamycin propionate, a drug with highly variable kinetics, in healthy volunteers. Int J Clin Pharmacol Ther 1996; 34 (5): 202–7.
16. Georgopoulos A, Buxbaum A. Josamycin – das bessere Makrolid? Antibiotika monitor 2004; 4. http://www.antibiotikamonitor.at/4_04/4_04_1.htm

С.В.Яковлев1, Е.В.Довгань2,3

1 ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России;
2 ОГБУЗ Смоленская областная клиническая больница;
3 АНО Институт клинической фармакологии, Смоленск